Patients with TGCT are encouraged to honestly discuss their pain with their care teams. Patients with TGCTs, or tenosynovial giant cell tumors, often have to deal with pain and discomfort as a result ...
A polygenic risk score (PRS) analysis reported that familial testicular germ cell tumours (TGCTs) were significantly enriched for TGCT risk alleles and that ≥84% were attributable to polygenic ...
An Ono Pharma drug for a type of tumor affecting tissues of the joints is now FDA approved, giving the Japanese company a product with dosing and safety advantages over the Daiichi Sankyo product that ...
REDWOOD CITY, Calif., Oct. 20, 2021 (GLOBE NEWSWIRE) -- AmMax Bio, Inc. (“AmMax”), a private clinical-stage biotech company developing novel treatments with AMB-05X, its proprietary anti-CSF1R ...
Ono Pharmaceutical has claimed FDA approval for Romvimza as a treatment for tenosynovial giant cell tumour (TGCT), setting up a market tussle with Daiichi Sankyo. CSF-1R inhibitor Romvimza ...
(RTTNews) - Deciphera Pharmaceuticals, Inc. (DCPH) Monday announced positive top-line results from the pivotal Phase 3 MOTION study of its investigational drug Vimseltinib in patients with ...
Tenosynovial giant cell tumor (TGCT) is a condition in which tumors form in the tissues of joints, causing pain and swelling in the affected area. It can be difficult to stay active if you have TGCT, ...
OSAKA, Japan & WALTHAM, Mass., October 18, 2025--(BUSINESS WIRE)--Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; "Ono"), today announced the two-year ...
The U.S. Food and Drug Administration (FDA) has approved vimseltinib (Romvimza) for adult patients with a rare condition called tenosynovial giant cell tumor (TGCT). TGCT is a tumor of the tissue that ...
Watch a webinar as experts on tenosynovial giant cell tumor (TGCT) share an overview of TGCT and a simple summary of the MOTION study. ROMVIMZA is a prescription medicine used to treat adults with ...
A partial halt has been put on the phase 3 ENLIVEN study, which is investigating the use of the novel oral CSF-1R inhibitor pexidartinib (PLX3397) in the treatment of tenosynovial giant cell tumor ...
Vimseltinib is the first and only therapy with marketing authorization for the treatment of TGCT in the European Union OSAKA, Japan & WALTHAM, Mass.--(BUSINESS WIRE)--Ono Pharmaceutical Co., Ltd.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results